NCR Online Journal

Acne Vulgaris Pipeline Insights 2021: DelveInsight

 Breaking News
  • No posts were found

Acne Vulgaris Pipeline Insights 2021: DelveInsight

October 14
04:55 2021
Acne Vulgaris Pipeline Insights 2021: DelveInsight

Acne Vulgaris Overview

Acne Vulgaris is a common chronic inflammatory disease of the skin. It is a disease that affects the pilosebaceous units of the skin and may result in inflammatory or non-inflammatory lesions. Acne Vulgaris can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. The study of the Global Burden of Disease (GBD) reported that AV affects about 85% of young adults aged 12-25 years.

 

DelveInsight’s, Acne Vulgaris Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Acne Vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Download Free Sample Reporthttps://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight

 

Acne Vulgaris Companies

  • Sol-Gel Technologies
  • Bausch Health Companies
  • AOBiome
  • Boston Pharmaceuticals
  • Eligo Bioscience
  • Suzhou Kintor Pharmaceuticals
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Vicuron Pharmaceuticals
  • Galderma
  • And many others

 

Acne Vulgaris Symptoms

Acne vulgari is characterized by noninflammatory, open or closed comedones and by inflammatory papules, pustules, and nodules. Symptoms of AV are known to be affecting the occurrence of depression, leading to a lower quality of life in its patients, especially adolescents. Psychological comorbidities, including depression and anxiety, have been associated with AV.

 

Acne Vulgaris Causes

The four main factors that cause acne are:

• Excess oil (sebum) production

• Hair follicles clogged by oil and dead skin cells

• Bacteria

• Inflammation

 

Acne Vulgaris Pathogenesis

Acne affects the pilosebaceous units of the skin which presents with a variety of lesions at various inflammatory stages, including acne scars and hyperpigmentation. The four main pathological factors involved in the development of acne are the increased sebum production, irregular follicular desquamation, Propionibacterium acnes proliferation and inflammation of area.

 

Acne Vulgaris Diagnosis

The diagnosis is generally established by identifying of quantity and morphology of the lesions. Their morphologies are divided into the noninflammatory comedones, termed as open (blackheads) or closed (whiteheads) and the inflammatory lesions, termed as papules, pustules, cyst, or nodules. There are several of differential diagnosis of AV, such as acne rosacea, folliculitis and boils, milia, and pityrosporum folliculitis.

 

Acne Vulgaris Treatment

The main goal of acne treatment is to control and treat existing acne lesions, prevent permanent scarring as far as possible, limit the duration of the disorder and to minimize morbidity. Treatment options includes topical therapies (retinoids, and antibiotics), systemic therapies (retinoids, antibiotics, and hormonal), and complementary and alternative medicines (CAM). The physical therapies such as comedone extraction, cryoslush therapy, cryotherapy, electrocauterization, intralesional corticosteroids and optical treatments are also used.

 

Acne Vulgaris Emerging Drugs

  • Twyneo: Sol-Gel Technologies
  • BOS-356: Boston Pharmaceuticals

 

Inquire Buying Reporthttps://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight

 

Table of Content

  • Introduction
  • Executive Summary
  • Acne Vulgaris: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • Acne Vulgaris – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • Acne Vulgaris Collaboration Deals
  • Late Stage Products (Phase III)
  • IDP 126: Bausch Health Companies
  • Mid Stage Products (Phase II/III)
  • Ivermectin topical: Galderma
  • Early Stage Products (Phase I)
  • BOS-356: Boston Pharmaceuticals
  • Preclinical/Discovery Stage Products
  • EB-005: Eligo Bioscience
  • Inactive Products
  • Acne Vulgaris Key Companies
  • Acne Vulgaris Key Products
  • Acne Vulgaris- Unmet Needs
  • Acne Vulgaris- Market Drivers and Barriers
  • Acne Vulgaris- Future Perspectives and Conclusion
  • Acne Vulgaris Analyst Views
  • Acne Vulgaris Key Companies
  • Appendix

 

Request Free Sample Report https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

 

Contact Us

Yash

[email protected]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles